Table 2. Genotype distributions in stent thrombosis (ST) and non-ST groups.
| *ST group | Non-ST group | ||||
| Genotypes | (n = 20) | (n = 40) | Total | P value | |
| CYP 2C19 * 2 | *2/*2 (AA) | 4 (20%) | 4 (10%) | 8 (13.3%) | 0.038 |
| wt/*2 (GA) | 11 (55%) | 12 (30%) | 23 (38.3%) | ||
| wt/wt (GG) | 5 (25%) | 24 (60%) | 29 (48.4%) | ||
| CYP 2C19 * 3 | AA | 0 | 0 | 0 | 0.591 |
| AG | 2 (10%) | 6 (15%) | 8 (13.3%) | ||
| GG | 18 (90%) | 34 (85%) | 52 (86.7%) | ||
| CYP 2C19 * 17 | TT | 0 | 0 | 0 | - |
| CT | 0 | 0 | 0 | ||
| CC | 20 (100%) | 40 (100%) | 60 (100%) | ||
| PON1 Q192R | RR192 | 10 (50%) | 17 (42.5%) | 27 (45%) | 0.760 |
| QR192 | 7 (35%) | 18 (45%) | 25 (41.7%) | ||
| QQ192 | 3 (15%) | 5 (12.5%) | 8 (13.3%) | ||
| PON1 L55M | AA | 0 | 0 | 0 | 0.309 |
| AT | 1 (5%) | 2 (5%) | 3 (5%) | ||
| TT | 19 (95%) | 38 (95%) | 57 (95%) | ||
| PON1 108C>T | TT | 5 (25%) | 8 (20%) | 13 (21.7%) | 0.873 |
| TC | 10 (50%) | 20 (50%) | 30 (50%) | ||
| CC | 5 (25%) | 12 (30%) | 17 (28.3%) | ||
| ABCB1 C3435T | TT | 6 (30%) | 5 (12.5%) | 11 (18.3%) | 0.188 |
| TC | 9 (45%) | 18 (45%) | 27 (45%) | ||
| CC | 5 (25%) | 17 (42.5%) | 22 (36.7%) | ||
| ABCB1 T129C | CC | 0 | 0 | 0 | 0.509 |
| CT | 1 (5%) | 4 (10%) | 5 (8.3%) | ||
| TT | 19 (95%) | 36 (90%) | 55 (91.7%) | ||
| ABCB1 G2677T | TT | 5 (25%) | 6 (15%) | 11 (18.3%) | 0.544 |
| TA | 3 (15%) | 4 (10%) | 7 (11.7%) | ||
| TG | 6 (30%) | 13 (32.5%) | 19 (31.7%) | ||
| GA | 2 (10%) | 10 (25%) | 12 (20%) | ||
| AA | 0 | 2 (5%) | 2 (3.3%) | ||
| GG | 4 (20%) | 5 (12.5%) | 9 (15%) | ||
*
ST, stent thrombosis.
The genotype frequencies of PON1, CYP, and ABCB1 polymorphisms in the stent thrombosis (ST) and non-ST groups. A significant difference (P = 0.038) in genotype distribution between the ST and non-ST groups is seen only for CYP 2C19*2 and not for PON1, CYP 2C19*3, CYP 2C19*17, and ABCB1 polymorphisms.